Chelating properties of tripeptide-9 citrulline

Tripeptide-9 Citrulline (INCI name) is a peptide with skin care properties, used for cosmetic applications. In order to elucidate its mechanism of action in the chemical pathways that involve metal ions, its ability to complex such ions was investigated using spectrophotometrical, electrochemical and electrophoretical techniques. The obtained results using Cu(II) as metal ion were consistent with the formation of a complex between Tripeptide-9 Citrulline andCu(II). Cyclic voltammetry revealed a significant changein the electrochemical potentials. In-vitro electrophoretic studies served as a proof of concept that Tripeptide-9 Citrullinemay protect DNA from radical degradation induced by the Fenton reaction

Propietats de coordinació de Tripeptide-9-citrulline

Tripeptide-9 Citrulline (INCI name) is a peptide with skin care properties, used for cosmetic applications. In order to elucidate its mechanism of action in the chemical pathways that involve metal ions, its ability to complex such ions was investigated using spectrophotometrical, electrochemical and electrophoretical techniques. The obtained results using Cu(II) as metal ion were consistent with the formation of a complex between Tripeptide-9 Citrulline and Cu(II). Cyclic voltammetry revealed a significant change in the electrochemical potentials. In-vitro electrophoretic studies served as a proof of concept that Tripeptide-9 Citrulline may protect DNA from radical degradation induced by the Fenton reaction.Tripeptide-9-citrulline (nombre INCI) es un péptido para el cuidado de la piel, usado en aplicaciones cosméticas. Para elucidar su mecanismo de acción en aquellas vías químicas que implican iones metálicos, se ha estudiado su capacidad para formar complejos metálicos. Dicho estudio se ha llevado a cabo utilizando técnicas espectrofotométricas, electroquímicas y electroforéticas. Los resultados obtenidos, usando Cu (II) como ión metálico, son consistentes con la formación de un complejo entre Tripeptide-9-citrulline y el ion metálico. La voltametría cíclica ha revelado un cambio significativo en los potenciales electroquímicos. Finalmente se ha demostrado mediante experimentos de electroforéticos que Tripeptide-9-citrulline podría proteger el ADN de la degradación inducida por los radicales producidos en la reacción de Fenton.Tripeptide-9-citrulline (Nom INCI) és un pèptid usat en aplicacions cosmètiques que tenen cura de la pell. Per a elucidar el seu mecanisme d’acció en aquelles vies químiques que involucren ions metàl·lics, s‘ha estudiat la seva capacitat per a format complexos metàl·lics. Aquest estudi s’ha dut a terme utilizant tècniques espectrofotomètriques, electroquímiques i electroforètiques. Els resultats obtinguts, emprant (II) com a ió metàl·lic, són consistents amb la formació d’un complex entre Tripeptide-9-citrulline i el ió metàl·lic. La voltametria cíclica revela un canvi significatiu entre els potencials electroquímics. Finalment, s’ha demostrat mitjançant experiments electroforètics que Tripeptide-9-citrulline podria protegir l’ADN de la degradació induïda pels radicals produïts en la reacció de Fenton

Use of piretanide, a new loop diuretic in cirrhosis with ascites. Relationship between the diuretic response and the plasma aldosterone level

Twenty patients with cirrhosis and ascites but no renal failure were given piretanide, a new loop diuretic, in order to investigate its efficacy and to relate the diuretic response with the pretreatment plasma aldosterone concentration. Eleven patients responded to piretanide 12 mg/day (equivalent in potency to 80 mg furosemide); there was no response in nine patients. Both groups were similar with regard to liver function, plasma urea, serum creatinine, plasma electrolytes, urine volume, and urine potassium concentration. The basal urinary sodium excretion was significantly higher in those patients who responded (23.6 +/- 5.7 mmol/day vs. 4.3 +/- 1.42 mmol/day; P < 0.01) (M +/- SE). Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were normal or only slightly increased in patients who responded to piretanide (PRA = 1.22 +/- 0.20 ng/ml/h; PAC = 12.25 +/- 2.20 ng/100 ml) and very high in patients who did not respond (PRA = 8.71 +/- 1.18 ng/ml/h; PAC = 84.6 +/- 16.2 ng/100 ml) (P < 0.001). Patients unresponsive to piretanide 12 mg/day also failed to respond when the dose was increased to 24 mg/day. However, the addition of spironolactone, 150 mg/day, to piretanide was followed in these patients by a marked increase in diuresis and natriuresis. These results strongly suggest that the pre-treatment level of aldosterone is an important factor influencing the response to loop diuretics in patients with non-azotaemic cirrhosis and ascites